Clinical trial
Temodar and Sutent as Therapy for Melanoma
NCT00304200 · Northern California Melanoma Center, Other · Terminated
Key facts
| NCT number | NCT00304200 |
|---|---|
| Title | Temodar and Sutent as Therapy for Melanoma |
| Official title | Temodar and Sutent as Therapy for Patients With Malignant Melanoma, a Phase I/II Study |
| Lead sponsor | Northern California Melanoma Center, Other |
| Collaborators | Pfizer Industry Schering-Plough |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Malignant Melanoma |
| Intervention type | Drug |
| Interventions | Temozolomide and SU11248 |
| Enrollment | 7 |
| Start date | Mar 1, 2006 |
| Primary completion | Oct 1, 2007 |
| Completion | Jan 1, 2009 |
| First posted | Mar 17, 2006 |
| Last update posted | Feb 5, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: